Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
<h4>Unlabelled</h4>In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate of risk of HIV-1 infection. To determine if V1V2-specific Abs cross-react with V1V2 from di...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/908050f48a3743e69cae612588e66678 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:908050f48a3743e69cae612588e66678 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:908050f48a3743e69cae612588e666782021-11-18T08:33:56ZVaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.1932-620310.1371/journal.pone.0087572https://doaj.org/article/908050f48a3743e69cae612588e666782014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24504509/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Unlabelled</h4>In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate of risk of HIV-1 infection. To determine if V1V2-specific Abs cross-react with V1V2 from different HIV-1 subtypes, if the nature of the V1V2 antigen used to asses cross-reactivity influenced infection risk, and to identify immune assays for upcoming HIV-1 vaccine efficacy trials, new V1V2-scaffold antigens were designed and tested. Protein scaffold antigens carrying the V1V2 regions from HIV-1 subtypes A, B, C, D or CRF01_AE were assayed in pilot studies, and six were selected to assess cross-reactive Abs in the plasma from the original RV144 case-control cohort (41 infected vaccinees, 205 frequency-matched uninfected vaccinees, and 40 placebo recipients) using ELISA and a binding Ab multiplex assay. IgG levels to these antigens were assessed as correlates of risk in vaccine recipients using weighted logistic regression models. Levels of Abs reactive with subtype A, B, C and CRF01_AE V1V2-scaffold antigens were all significant inverse correlates of risk (p-values of 0.0008-0.05; estimated odds ratios of 0.53-0.68 per 1 standard deviation increase). Thus, levels of vaccine-induced IgG Abs recognizing V1V2 regions from multiple HIV-1 subtypes, and presented on different scaffolds, constitute inverse correlates of risk for HIV-1 infection in the RV144 vaccine trial. The V1V2 antigens provide a link between RV144 and upcoming HIV-1 vaccine trials, and identify reagents and methods for evaluating V1V2 Abs as possible correlates of protection against HIV-1 infection.<h4>Trial registration</h4>ClinicalTrials.gov NCT00223080.Susan Zolla-PaznerAllan deCampPeter B GilbertConstance WilliamsNicole L YatesWilliam T WilliamsRobert HowingtonYouyi FongDaryl E MorrisKelly A SoderbergCarmela IreneCharles ReichmanAbraham PinterRobert ParksPunnee PitisuttithumJaranit KaewkungwalSupachai Rerks-NgarmSorachai NitayaphanCharla AndrewsRobert J O'ConnellZhi-yong YangGary J NabelJerome H KimNelson L MichaelDavid C MontefioriHua-Xin LiaoBarton F HaynesGeorgia D TomarasPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e87572 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Susan Zolla-Pazner Allan deCamp Peter B Gilbert Constance Williams Nicole L Yates William T Williams Robert Howington Youyi Fong Daryl E Morris Kelly A Soderberg Carmela Irene Charles Reichman Abraham Pinter Robert Parks Punnee Pitisuttithum Jaranit Kaewkungwal Supachai Rerks-Ngarm Sorachai Nitayaphan Charla Andrews Robert J O'Connell Zhi-yong Yang Gary J Nabel Jerome H Kim Nelson L Michael David C Montefiori Hua-Xin Liao Barton F Haynes Georgia D Tomaras Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. |
| description |
<h4>Unlabelled</h4>In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate of risk of HIV-1 infection. To determine if V1V2-specific Abs cross-react with V1V2 from different HIV-1 subtypes, if the nature of the V1V2 antigen used to asses cross-reactivity influenced infection risk, and to identify immune assays for upcoming HIV-1 vaccine efficacy trials, new V1V2-scaffold antigens were designed and tested. Protein scaffold antigens carrying the V1V2 regions from HIV-1 subtypes A, B, C, D or CRF01_AE were assayed in pilot studies, and six were selected to assess cross-reactive Abs in the plasma from the original RV144 case-control cohort (41 infected vaccinees, 205 frequency-matched uninfected vaccinees, and 40 placebo recipients) using ELISA and a binding Ab multiplex assay. IgG levels to these antigens were assessed as correlates of risk in vaccine recipients using weighted logistic regression models. Levels of Abs reactive with subtype A, B, C and CRF01_AE V1V2-scaffold antigens were all significant inverse correlates of risk (p-values of 0.0008-0.05; estimated odds ratios of 0.53-0.68 per 1 standard deviation increase). Thus, levels of vaccine-induced IgG Abs recognizing V1V2 regions from multiple HIV-1 subtypes, and presented on different scaffolds, constitute inverse correlates of risk for HIV-1 infection in the RV144 vaccine trial. The V1V2 antigens provide a link between RV144 and upcoming HIV-1 vaccine trials, and identify reagents and methods for evaluating V1V2 Abs as possible correlates of protection against HIV-1 infection.<h4>Trial registration</h4>ClinicalTrials.gov NCT00223080. |
| format |
article |
| author |
Susan Zolla-Pazner Allan deCamp Peter B Gilbert Constance Williams Nicole L Yates William T Williams Robert Howington Youyi Fong Daryl E Morris Kelly A Soderberg Carmela Irene Charles Reichman Abraham Pinter Robert Parks Punnee Pitisuttithum Jaranit Kaewkungwal Supachai Rerks-Ngarm Sorachai Nitayaphan Charla Andrews Robert J O'Connell Zhi-yong Yang Gary J Nabel Jerome H Kim Nelson L Michael David C Montefiori Hua-Xin Liao Barton F Haynes Georgia D Tomaras |
| author_facet |
Susan Zolla-Pazner Allan deCamp Peter B Gilbert Constance Williams Nicole L Yates William T Williams Robert Howington Youyi Fong Daryl E Morris Kelly A Soderberg Carmela Irene Charles Reichman Abraham Pinter Robert Parks Punnee Pitisuttithum Jaranit Kaewkungwal Supachai Rerks-Ngarm Sorachai Nitayaphan Charla Andrews Robert J O'Connell Zhi-yong Yang Gary J Nabel Jerome H Kim Nelson L Michael David C Montefiori Hua-Xin Liao Barton F Haynes Georgia D Tomaras |
| author_sort |
Susan Zolla-Pazner |
| title |
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. |
| title_short |
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. |
| title_full |
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. |
| title_fullStr |
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. |
| title_full_unstemmed |
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. |
| title_sort |
vaccine-induced igg antibodies to v1v2 regions of multiple hiv-1 subtypes correlate with decreased risk of hiv-1 infection. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/908050f48a3743e69cae612588e66678 |
| work_keys_str_mv |
AT susanzollapazner vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT allandecamp vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT peterbgilbert vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT constancewilliams vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT nicolelyates vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT williamtwilliams vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT roberthowington vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT youyifong vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT darylemorris vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT kellyasoderberg vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT carmelairene vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT charlesreichman vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT abrahampinter vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT robertparks vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT punneepitisuttithum vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT jaranitkaewkungwal vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT supachairerksngarm vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT sorachainitayaphan vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT charlaandrews vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT robertjoconnell vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT zhiyongyang vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT garyjnabel vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT jeromehkim vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT nelsonlmichael vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT davidcmontefiori vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT huaxinliao vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT bartonfhaynes vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection AT georgiadtomaras vaccineinducediggantibodiestov1v2regionsofmultiplehiv1subtypescorrelatewithdecreasedriskofhiv1infection |
| _version_ |
1718421635077242880 |